For this reason, in this case-series study, the potential real-world benefits of switching Taiwanese diabetes patients (T1DM and T2DM) from Gla-100 to Gla-300 for basal insulin therapy to minimize nocturnal glucose variability were investigated through continuous glucose monitoring (CGM). This evidence concerns the gene INS and type 1 diabetes mellitus.